ASCO 2025 Highlights

Jun 06, 2025
Episode
293
Share

This episode of Lung Cancer Considered reviews important lung cancer data presented at ASCO 2025. Lung Cancer Considered hosts Dr. Narjust Florez and Dr. Stephen Liu are joined by Dr. Charu Aggarwal and Dr. Patrick Forde to discuss several of the most significant lung cancer trials presented at ASCO, including the CheckMate 816, the phase III HERTHENA-Lung02 study, the NEOADAURA study, the REZILIENT1 study, the SWOG Pragmatica study, the IMforte study and the SOHO-01 trial.

Guest
Narjust Florez
Narjust Florez

MD

Associate Director of the Cancer Care Equity Program and Assistant Professor of Medicine
Dana-Farber Cancer Institute
Harvard Medical School
Stephen Liu
Stephen Liu

MD

Associate Professor of Medicine, Director of Thoracic Oncology and Director of Developmental Therapeutics
Georgetown Lombardi Comprehensive Cancer Center
Charu Aggarwal
Charu Aggarwal

MD, MPH

Leslye M. Heisler Associate Professor for Lung Cancer Excellence
University of Pennsylvania
Patrick Forde
Patrick Forde

MD, M.B.B.Ch.

Director of Thoracic Oncology - Clinical Research Program and Associate Professor
John Hopkins University

Other Podcast